Navigation Links
New Data for XL880, XL647 and XL184 to Be Presented at AACR-NCI-EORTC
Date:10/8/2007

- A Total of 13 Abstracts for Eight Compounds Being Presented - - Investor Briefing to be Webcast on October 24, 2007 at 6:00 PM PDT -

SOUTH SAN FRANCISCO, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today announced that data from ongoing phase 2 trials of XL880 and XL647 in papillary renal cell carcinoma and non-small cell lung cancer, respectively, will be presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held October 22-26, 2007 in San Francisco. In addition, phase 1 data for XL184, which inhibits MET, VEGFR2 and RET, will also be presented. In total, 13 abstracts for eight compounds have been accepted for poster presentation at the conference, reporting data from clinical trials or preclinical studies of XL880, XL647, XL184, XL147, XL765, XL820, XL844 and XL518.

"With 13 abstracts covering eight clinical-stage compounds, the 2007 AACR-NCI-EORTC meeting is an important opportunity to highlight the breadth and depth of our pipeline," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Critical to our goal of building a world-class oncology franchise is the rapid advancement of the 14 compounds currently in the clinic and the continued ability to advance additional compounds into development. We believe our strong presence at this meeting is evidence of our productivity. Three of the phase 1 compounds that will be discussed were preclinical compounds at this time last year and we will present phase 2 data from trials that were initiated less than 18 months ago."

Exelixis will hold a briefing for investors and analysts on Wednesday, October 24, 2007, from 6:00-8:00 p.m. PDT / 9:00-11:00 p.m. EDT. During the briefing, Exelixis management will review data for XL647, XL880 and XL184, in addition to other Exelixis compounds. This webcast may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com. An archive of the webcast will be available until 8:59 p.m. PST/11:59 p.m. EST on November 24, 2007. Access numbers for the replay are 1-888-286-8010 (domestic) and 1-617-801-6888 (international). The replay passcode is 86296035.

The full list of abstracts to be presented at the meeting follows:

Phase 2 Clinical Abstracts

-- A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients

(pts) with papillary renal carcinoma (PRC) (Abstract #B249)

-- A Phase II study of XL647 in Patients with Non-Small Cell Lung Cancer

(NSCLC) Enriched for Presence of EGFR Mutations (Abstract #B124)

Phase 1 Clinical Abstracts

-- A phase 1 dose-escalation study of the safety and pharmacokinetics (PK)

of XL184, a VEGFR and MET kinase inhibitor, administered orally to

patients (pts) with advanced malignancies (Abstract #A152)

-- A phase I dose-escalation study of the safety, pharmacokinetics, and

pharmacodynamics of XL820 administered orally daily (QD) or twice daily

(BID) to patients (pts) with solid malignancies (Abstract #B69)

-- Targeting aberrant PI3K pathway signaling with XL147, a potent,

selective and orally bioavailable PI3K inhibitor (Abstract #C205)

-- Biomarker development for XL765, a potent and selective oral dual

inhibitor of PI3K and mTOR currently being administered to patients in

a Phase I clinical trial (Abstract #B265)

-- A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a

novel spectrum selective kinase inhibitor, administered orally daily to

patients with advanced solid malignancies (ASM) (Abstract #B242)

-- A Phase I dose-escalation study of the safety, pharmacokinetics (PK)

and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor,

administered daily to patients (pts) with advanced malignancies

(Abstract #B248)

Preclinical Abstracts

-- XL820 inhibits mutated forms of KIT associated with drug resistance

(Abstract #B237)

-- In vitro and in vivo potentiation of cytotoxic therapy by XL844, an

orally bioavailable inhibitor of Chk1 and Chk2 (Abstract #B228)

-- XL518, a Potent Selective Orally Bioavailable MEK1 Inhibitor,

Downregulates the RAS/RAF/MEK/ERK Pathway In Vivo, Resulting in Tumor

Growth Inhibition and Regression in Pre-Clinical Models (Abstract

#C209)

-- Potentiating the antitumor effects of chemotherapy with the selective

PI3K inhibitor XL147 (Abstract #C199)

-- XL765 targets tumor growth, survival, and angiogenesis in preclinical

models by dual inhibition of PI3K and mTOR (Abstract #B250)

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  EIP Pharma, LLC ( www.eippharma.com ) ... neflamapimod (previously code named VX-745), with the results ... that demonstrated significant Alzheimer,s disease relevant pharmacological activity.  ... Study 303 (6-week treatment) are the subject of ... (CTAD) scientific conference in San Diego, ...
(Date:12/8/2016)... Research and Markets has announced the addition of the ... ... global chromatography market to grow at a CAGR of 5.42% during the ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
(Date:12/8/2016)... 8, 2016  Economic growth in the United States ... supply management executives in their December 2016 Semiannual Economic ... recovery that began in mid-2009, as indicated in the ... ® . The manufacturing sector is optimistic about growth ... manufacturing industries, and the non-manufacturing sector indicates that 14 ...
Breaking Medicine Technology:
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... up in 2006 as a non-profit organization to unite pharmaceutical and healthcare companies ...
(Date:12/8/2016)... ... 2016 , ... STAT courier is pleased to announce that due to customer ... are expanding their presence in Dallas. One of the most exciting parts for STAT ... to the Dallas and Forth Worth market. STAT takes pride in treating their employees ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
(Date:12/8/2016)... , ... December 08, 2016 , ... Vida ... an $18M Series B led by Canvas Ventures . Other investors include Nokia ... scale its mobile platform to serve more consumers who are managing chronic conditions ...
Breaking Medicine News(10 mins):